Population-Based Prevalence of CDKN2A Mutations in Utah Melanoma Families  by Eliason, Mark J. et al.
Population-Based Prevalence of CDKN2A Mutations
in Utah Melanoma Families
Mark J. Eliason1,2, April A. Larson1,2, Scott R. Florell1,2, John J. Zone1,2, Lisa A. Cannon-Albright2,3,
Wolfram E. Samlowski2,4 and Sancy A. Leachman1,2
Cyclin-dependent kinase inhibitor 2A (CDKN2A or p16) is the major melanoma predisposition gene. In order to
evaluate the candidacy for genetic testing of CDKN2A mutations among melanoma prone families, it is
important to identify characteristics that predict a high likelihood of carrying a CDKN2A mutation. We primarily
used a unique Utah genealogical resource to identify independent melanoma prone families whom we tested
for mutations in CDKN2A, cyclin-dependent kinase 4, and alternate reading frame. We sampled 60 families
which met the inclusion criteria of two or more affected first-degree relatives. We found four different
pathogenic CDKN2A mutations in five families, mutations of uncertain significance in two families, and known
polymorphisms in three families. One of the mutations of uncertain significance, 50 untranslated region
25C4T, has not been previously described. Among our population-based set of Utah families, the prevalence
of CDKN2A mutations was 8.2% (4/49); the overall prevalence when physician-referred pedigrees were also
considered was between 8.3% (5/60) and 10% (6/60). Having four or more first- or second-degree relatives with
melanoma, or a family member with X3 primary melanomas, correlated strongly with carrying a CDKN2A
mutation. We observed a significantly elevated rate of pancreatic cancer in one of four families with a
deleterious CDKN2A mutation.
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INTRODUCTION
Melanoma is a devastating malignancy and the most lethal of
all skin cancers. Among the top 10 most common cancers in
the United States (US) between 1992 and 2001, melanoma
had the highest rate of increase in incidence in men and the
second highest in women (Jemal et al., 2004). Familial
melanoma refers to the clustering of several cases within a
single family and accounts for about 5–12% of melanoma
cases (Goldstein and Tucker, 2001). Being a member of a
melanoma-prone family has been associated with a 35–70-
fold increase in the relative risk of developing a melanoma
(Kefford et al., 1999; Piepkorn, 2000). Three germline
melanoma predisposition gene products have been identi-
fied, cyclin-dependent kinase inhibitor 2A (CDKN2A or p16)
(Cannon-Albright et al., 1994; Hussussian et al., 1994; Kamb
et al., 1994), cyclin-dependent kinase 4 (CDK4) (Zuo et al.,
1996), and alternate reading frame (ARF) (Randerson-Moor
et al., 2001). The CDKN2A gene locus encodes both the p16
and ARF transcripts. Mutations that affect p16 function have
been reported in 25–40% of melanoma prone families, while
mutations in CDK4 and ARF are relatively rare, accounting
for o1% of familial melanomas (Piepkorn, 2000; Hayward,
2003). In this article, CDKN2A variants that affect p16 will be
referred to as ‘‘CDKN2A mutations’’.
p16 is a key cell cycle regulatory molecule that inhibits
CDK4/6-dependent phosphorylation of retinoblastoma pro-
tein to block entry into the G1/S phase of the cell cycle (Ruas
and Peters, 1998; Hayward, 2003). The functional result of
germline CDK4 mutations is a loss of ability for this protein to
be bound and thus inhibited by p16, resulting in dysregula-
tion of the same retinoblastoma cell cycle pathway. Though
also coded by the CDKN2A gene locus, ARF is a distinct
tumor suppressor that functions through the human double
minute 2 pathway regulating the degradation of p53 (Zhang
et al., 1998). Mutations in each of these gene products have
been found to cosegregate with melanoma in familial
melanoma pedigrees (Zuo et al., 1996; Goldstein et al.,
2000; Randerson-Moor et al., 2001; Soufir et al., 2004).
Since CDKN2A was identified as the major melanoma
susceptibility gene, groups from around the world have
identified melanoma-prone families and reported the pre-
valence rate of CDKN2A mutations among them. These
studies have identified clinical features associated with
CDKN2A mutation-positive families, including multiple
affected relatives, family members with multiple primary
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melanomas, and the presence of some nonmelanoma cancers
(eg pancreatic cancer) (Vasen et al., 2000; Lynch et al., 2002;
Puig et al., 2005). Previous reports of p16 mutation rates in
familial melanomas are summarized in Table 1. Among these
studies, the standard for what constitutes ‘‘familial’’ predis-
position to melanoma has varied significantly, with inclusion
criteria ranging from any person with multiple primaries to at
least three affected first-degree relatives over two generations.
These differences in inclusion parameters can be well
understood in the context of the differing incidences of
sporadic melanoma among the respective populations (eg the
UK has about 10 cases per 100,000 per year, while Australia
reports an annual incidence of about 50 cases per 100,000
per year (Maclennen et al., 1992). However, the differences
in defining ‘‘familial melanoma’’ also make the comparison
of these data difficult.
In the majority of studies, participants were recruited from
melanoma registries created from melanoma clinics. These
registries often rely on participant reports of family history, and
data are often limited or inaccurate because the participant (1)
may be unfamiliar with his own family tree, (2) has limited
knowledge of melanomas within his family, or (3) does not
know the difference between melanoma and nonmelanoma
skin cancers. In addition, although it is relatively straightfor-
ward to confirm the reported cases of melanoma within a
family, the effort required to establish that all other family
members are truly unaffected is cost prohibitive. Furthermore,
in registries developed within tertiary referral or academic
centers, there is potential for referral bias of individuals with
the most dramatic clinical presentations. The clearest
approach to avoid this ascertainment and referral bias is to
use a population-based recruitment strategy, as was first done
by Platz et al. (1997). The impact of recall bias can also be
lessened by utilizing existing genealogic records.
The Utah Population Database (UPDB) is a research
resource at the University of Utah that contains information
for over six million unique individuals using genealogy
records from the Family History Library, vital records from the
Utah State Department of Health, and other statewide data
sets, as described in Florell et al. (2005). Information from
Utah birth certificates has been successfully linked to the
original genealogies to extend the data to the most recent
birth cohorts; thus, the genealogy records represent pedigrees
that may span up to 10 generations. Birth records are also
used to create multigenerational Utah families that were not
part of the original data set. These genealogical records are
linked to the Utah Cancer Registry, a Surveillance, Epide-
miology and End Results Cancer Registry, that has recorded
all invasive cancers in Utah since 1966. The combination of
statewide cancer records with genealogy data in the UPDB
provides a way to objectively confirm cancers in family
members and to identify the inter-relatedness among cancer
Table 1. Reported p16 mutation rates
Study location Author (year) Families studied p16 prevalence Definition of melanoma-prone family
Poland Lamperska et al. (2002) 16 0 (0%) One or two MM cases in the family
Utah, USA Kamb et al. (1994) 36 2 (6%) Either one MM case and two cases of DNS or at least
two MM cases per family
NE, Italy Landi et al. (2004) 55 4 (7%) Two cases of MM in the family
Israel Yakobson et al. (2000) 30 2 (7%) Two cases or MPM
Sweden Platz et al. (1997)1 64 5 (8%) Two or more cases of MM (first-, second-, or
third-degree relatives)
Australia Holland et al. (1999) 131 11 (8.4%) At least two MM cases
Australia Aitken et al. (1999) 87 9 (10%) Population-based, high-risk status assigned based on
the number of cases, age or melanoma, sex and birth
cohorts
Spain Ruiz et al. (1999) 34 6 (17%) At least one w/ MM and one w/ DNS
Massachusets, USA Fitzgerald et al. (1996) 28 5 (18%) Two cases of MM (must be first- or second-degree
relative)
Australia Flores et al. (1997) 48 10 (21%) Three cases of MM in two consecutive generations
UK Harland et al. (1997) 27 6 (22%) Two cases of MM or MPM
Scotland Mackie et al. (1998) 16 6 (38%) Two cases of MM
Italy Fargnoli et al. (1998) 10 4 (40%) 2 cases of MM in first- or second-degree relatives
France Soufir et al. (1998) 48 21 (44%) Three cases of MM, or two cases if one before age
50. Also at least one MPM OR relative w/Panc CA,
or two affected first-degree relatives
Total 630 91 (14%)
1This was the first population-based assessment of p16 prevalence rate.
MM=melanoma; MPM=multiple primary melanomas; DNS=dysplastic nevus syndrome; Panc CA=pancreatic adenocarcinoma.
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cases. By calculating the internal rates of cancer, the UPDB
can be used to determine whether a significant excess of
cancer exists in a specific family (Cannon Albright et al.,
2005). The use of the UPDB to identify and characterize
high-risk melanoma families limits biases associated with
physician referral and patient recall.
RESULTS
Mutation status
Table 2 summarizes data on the CDKN2A mutations we
found that were deleterious, of uncertain significance, or
polymorphisms. Among the 60 families tested, we identified
four previously described deleterious CDKN2A mutations in
five families. In addition to two polymorphisms (A148T, and
33 50untranslated region (UTR) G4C) and a mutation of
uncertain significance (A4T) also previously described, we
found one novel mutation in exon 1 at 50 UTR –25, resulting
in a G4C transition in one family that had two members with
melanoma. We were only able to recruit and test the two
affected individuals, a parent and child. The parent devel-
oped two primary melanomas, in the seventh decade of life,
and the child developed a melanoma in its 30s. Both were
25 mutation carriers.
We estimate the proportion of familial melanoma (defined
as a cluster of two or more first-degree relatives) due to
mutations that affect p16 to be between 8.3% (5/60) and 10%
(6/60), depending on whether or not the 50UTR 25 change
is determined to be deleterious. The A4T mutation did not
cosegregate with disease in our families. We found no
mutations in ARF or CDK4 in any of the 60 families.
CDKN2A mutations and the number of affected first-
and second-degree relatives
Table 3 summarizes the mutation screening results and
clinical characteristics for the 60 families, according to the
number of cases of melanoma in first- and second-degree
relatives of the proband. We found six families with four or
more affected first- or second-degree relatives, 18 families
with three affected relatives, and 36 families with two
affected first- or second-degree relatives. We did not count
known affected members more distant than second-degree
relation to the tested individuals because it is unusual in
clinical practice for patients to accurately know the
melanoma history of family members who are distantly
related. Table 3 summarizes the frequency of CDKN2A
variants by number of affected first- and second-degree
relatives in the family. In all, 50% of the families with four or
more first- or second-degree relatives affected had a known
deleterious CDKN2A mutation.
Multiple primary melanomas
We identified nine families with individuals who had
multiple primary melanomas. In Table 4, we show the
association of the maximum number of primary melanomas
Table 2. p16 Variants identified in the 60 Utah families





50UTR –34G4T Exon 1 Deleterious/Liu et al. (1999) New start site 2 Yes
V126D Exon 2 Deleterious/Hussussian et al. (1994) Missense 1 Yes
G101W Exon 2 Deleterious/Hussussian et al. (1994) Missense 1 Yes
32ins24 Exon 1 Deleterious/Harland M. et al. Insertion 1 Yes
A148T Exon 2 Polymorphism/Hussussian et al. (1994) Missense 3 No
50UTR –33G4C Exon 1 Polymorphism/Soufir et al. (1998) None known 1 No
A4T Exon 2 Unknown significance Unknown 1 No
50UTR –25C4T Exon 1 Unknown significance Unknown 1 Yes
1Data on mutational effect obtained through eMelanobase website (Melanoma Genetics Consortium, 2005).




Number of melanomas in
first- and second-degree
relatives including proband
Total number of families
(% of total) Total Percent Total Percent Total Percent
2 36 (60) 1 3 1 3 2 6
3 18 (30) 1 7 1 7 0 0
X4 6 (10) 3 50 0 0 0 0
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observed in an individual with the results of the CDKN2A
mutation testing in their family. Four of the nine families
(44%) with multiple primary melanomas had a CDKN2A
mutation. All three pedigrees with members that had three or
more primary melanomas had a mutation in CDKN2A. Only
one of the six families with a member having two primary
melanomas had a mutation in CDKN2A. Of interest, this
individual reported having three primary melanomas, but we
were unable to confirm the third melanoma, resulting in
inclusion in the two primary melanomas category. Though
our sample size is limited, the strong correlation between
individuals with three or more primary melanomas and a
CDKN2A mutation in the Utah population is clear.
Pancreatic cancer in melanoma families
We found 22 families with at least one pancreatic cancer
case. In 18 of these families more pancreatic cancer cases
were observed than expected, but in only four of these
families was the excess significant (Po0.05).
DISCUSSION
The overall rate of deleterious CDKN2A mutations in our
familial melanoma pedigrees was significantly less (8.3–10%)
than the oft-quoted range of 25–40%. We observed that these
mutations (V126D, 34G4T, G101W, and 32ins24) cose-
gregated in our pedigrees (data not shown). We report one
novel mutation, 50UTR 25C4T, that cosegregated with
melanoma within the only family that carried it. We found
that the clinical characteristics associated with an elevated
risk of carrying a CDKN2A mutation in the Utah families are:
(1) having X4 first- or second-degree relatives with melano-
ma and (2) a first- or second- degree relative withX3 primary
melanomas. One of the families with a CDKN2A mutation
had a significant excess of pancreatic cancer.
The three features of the Utah pedigrees studied that need
to be considered in exploring why the CDKN2A mutation
rate was lower than expected are: (1) the high amount of UV
exposure in Utah due to the elevation and sunny environ-
ment, (2) the inclusion of previously studied high-risk
pedigrees, and (3) the largely population-based recruitment.
In the Salt Lake City vicinity, where about half the population
of Utah lives, the average elevation is 4,330 feet and it ranks
in the top quartile among US cities in the number of sunny
days per year (with over 120 on average). The increased UV
exposure in such an environment may explain the elevated
background rate of melanoma in Utah, which may in turn
lead to a larger number of first-degree affected individual
pairs where the precipitating cause is environmental and not
genetic. Large, well-defined CDKN2A-mutation-positive
pedigrees with thousands of family members have been
studied at our institution for the last 15 years. We include
these families as single families (see Table S1), rather than
breaking them into arbitrarily defined clusters of two or more
first-degree cases. This has the effect of reducing the rate of
CDKN2A mutations observed. In other published studies, it is
not uncommon for a majority of the CDKN2A carrier families
to have the same mutation (Mackie et al., 1998; Borg et al.,
2000; Mantelli et al., 2002), which leads to the speculation
that these families may represent parts of larger undefined
families like ours (‘‘founder effect’’). Among the five
CDKN2A mutation-positive families in this study, only two
had the same mutation, and we confirmed that there was no
genetic relationship between these families. The recruitment
of our families without the extensive genealogic data
available in Utah would have resulted in an artificially
elevated rate of CDKN2A mutations.
To minimize referral bias, we recruited largely from our
population database. We are aware of two other groups that
have used population-based recruitment, the first done in
Sweden and the other in Australia. In the Swedish study, Platz
et al. (1997) found the CDKN2A mutation rate in familial
melanoma to be 7.8%, while a study conducted later by Borg
et al. (2000) in the Swedish population used both referral-
and population-based means for recruitment, and reported a
mutation rate of 19%. In Australia, a population-based
assessment of the CDKN2A mutation rate carried out by
Aitken et al. (1999) reported a rate of 10.3%, while a previous
study that recruited participants through a registry reported a
rate of 20.8% (Flores et al., 1997). When Fitzgerald et al.
(1996) examined their melanoma-prone population in the
US, they found the rate of CDKN2A mutation carriage to be
about 18%. Our Utah population, has low inbreeding and is
representative of the general US Caucasian population (Jorde
et al., 2000). Four of the 49 (8.2%) families that we recruited
from a population-based resource had a deleterious CDKN2A
mutation. One to two of the 11 (9.1–18.2%) families that
were physician referrals had deleterious mutations. Combin-
ing the families recruited by population-based assessment
with physician referral had little effect on CDKN2A rate,
increasing the prevalence rate among our families to








(% of total) Total Percent Total Percent Total Percent
1 51 (85) 1 2 0 0 2 4
2 6 (10) 1 16 0 0 0 0
X3 3 (5) 3 100 0 0 0 0
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8.3–10%. Based on these observations, it is reasonable to
consider that the oft-quoted 25–40% rate of CDKN2A
mutations in melanoma-prone families may overestimate
the rate in the general melanoma-prone family population.
Novel CDKN2A mutation
We report one novel CDKN2A mutation (50UTR 25C4T),
found in one family that had two members with melanoma,
both of whom carried the mutation. Previous mutations have
been reported in the 50UTR region of CDKN2A, including the
34 G4T mutation, which creates a false start codon and is
a known deteterious mutation (Liu et al., 1999), and the 33
mutation, which is considered a polymorphism with no
proven adverse clinical effect (Soufir et al., 1998). A mutation
in the untranslated region of CDKN2A is unlikely to affect the
coding sequence to interfere with CKD4 binding. Other
functional testing (eg a retinoblastoma phosphorylation assay,
or an assay to assess cell cycle exit) may shed light on the
effect of this mutation. It is also worth noting that the 25
position is in a 289 bp CpG island (European Molecular
Biology Laboratory–European Bioinformatics Institute, Euro-
pean Bioinformatics Institute, 9 June 2005) containing
numerous MZF1- and SP1-binding sites (TF Search against
TRANSFAC matrix table rev. 3.3) and the G4C mutation
enriches and extends the local CpG island. Also, using the
interspecies alignment of the UCSC genome browser version
107 (bp 21,964,828–21,964,865), we found that the 24 and
25 basepairs are unanimously conserved across all mam-
malian species listed (human, chimp, dog, mouse, and rat) as
well as the zebrafish. It will be important to evaluate allele-
specific expression analysis in the future to determine
whether this is a pathogenic mutation.
CDKN2A and pancreatic cancer
Lynch and Fusaro (1991) reported a relationship between the
familial atypical mole syndrome and pancreatic cancer in the
early 1990s. Vasen et al. (2000) published work documenting
the strong association between a 19-bp deletion in CDKN2A
and pancreatic cancer in Dutch families, and several
CDKN2A prevalence studies have documented the occur-
rence of pancreatic cancer in melanoma-prone kindreds
(Fitzgerald et al., 1996; Soufir et al., 1998; Yakobson et al.,
2000; Parker et al., 2003; Landi et al., 2004). Using the
genealogic information available to us through the UPDB,
ours is the only study that has addressed the issue of whether
the rate of pancreatic cancer is significantly elevated in high-
risk melanoma families with and without CDKN2A muta-
tions. We are aware of some limitations inherent in relying on
a population database for this type of study. Cancers
occurring out of the state of Utah or prior to 1966 are
censored, and those cancer cases which do not link to
genealogical records are not analyzed. We expect that
there is no bias in such censoring, and that our estimates
of increased risk are conservative. We have used the
methods presented here in multiple studies of cancer risk
in the Utah population (Goldgar et al., 1994; Cannon
Albright et al., 2005). Among our 60 pedigrees, four had
significantly elevated rates of pancreatic cancer (see families
2, 11, 47, and 58 in Table S1), and one carried a CDKN2A
mutation.
In the face of the evidence reported by Vasen et al. (2000),
which clearly showed an excess rate of pancreatic cancer
among their melanoma-prone kindreds with the 19-bp
deletion (Leiden mutation), it seems reasonable to propose
that perhaps certain CDKN2A mutations confer greater risk of
both melanoma and pancreatic cancer than other mutations.
The elevation and sunny environment, which increase UV
exposure in our population, may lead to a preferential
expression of the melanoma phenotype without a similar
environmental factor to increase the rate of pancreatic cancer
(Bishop et al., 2002). The importance of establishing the risk
of other cancers or diseases associated with a CDKN2A
mutation is apparent as genetic testing for the CDKN2A
mutations becomes more readily available. Genetic counse-
lors and other health professionals may be challenged to
tailor their teaching and recommendations to the risks
associated with specific populations of CDKN2A carriers.
MATERIALS AND METHODS
Eligibility criteria
All patient recruitment was performed in accordance with protocols
approved by the University of Utah Institutional Review Board, and
all clinical investigation has been conducted according to the
Declaration of Helsinki Principles. All participants gave their written,
informed consent. We defined a melanoma-prone family as having
at least two first-degree relatives (a proband and a first-degree
relative) affected with invasive melanoma. This reasonably stringent
criterion limits recruitment of sporadic melanomas, and can be
easily applied in everyday clinical practice. We attempted to recruit
one or more melanoma cases from each pedigree for genetic testing,
preferentially recruiting the individuals affected at the youngest age
to decrease the chances of selecting a sporadic case.
Ascertainment
We used a population-based recruitment strategy to ascertain
families, querying the UPDB to identify families with at least two
first-degree relatives with melanoma. From over 4,000 cases of
invasive cutaneous melanoma for whom we also have genealogy
data available, we identified and recruited 49 independent sets of at
least two first-degree relatives with melanoma (families). Families
were defined as sets of related melanoma cases who had a common
ancestor, among whose descendants there was a significant excess of
melanoma cases, as determined by internally estimated rates of
melanoma. In addition, we accepted seven physician referrals and
four self-referrals that met our ascertainment criteria. These
physician and self-referrals were not identified in the UPDB as
either the diagnoses were too recent and not yet included in the
latest version of the UPDB, or a family member was diagnosed
outside the state of Utah. Melanoma diagnoses from physician or
self-referrals were objectively confirmed through medical records or
review of microscopic slides by a dermatopathologist (SRF).
Mutation testing
p16 mutation testing was performed by Myriad Genetics (Salt Lake
City) and Yale Diagnostics (New Haven). The entire coding region of
exon 1a, exon 2, exon 3, splice junctions, 50UTR, and a deep
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intronic region involved in a common splice mutation (Harland
et al., 2001) were sequenced in both the forward and reverse
directions. Exon 2 of CDK4 and exon 1b and the splice junctions of
the ARF genes were sequenced in the Yale Diagnostics Laboratory,
and revealed no additional mutations.
Melanoma confirmation
UPDB permits the identification of melanoma cases in large,
extended pedigrees, but this degree of information is not typically
available in a clinical practice. Therefore, we designed our study to
consider only the number of cases in a pedigree within a first- or
second-degree relationship in the evaluation of clinical features. In
the case where multiple individuals from a single kindred were
tested, we report the number of first- and second-degree relatives
from the tested member who had the most affected relatives.
We confirmed all diagnoses of melanoma in the participants and
their family members by the Utah Cancer Registry, medical records,
or death certificates.
Pancreatic cancer rates
We tested the hypothesis of a significant excess of pancreatic cancer
in each family using a previously published method (Cannon-
Albright et al., 2005; see Table S1). From the founding individual of
each family, we counted the observed number of pancreatic cancer
cases among all the descendants, and compared this to the expected
number of pancreatic cancer cases among all the descendants. The
expected number of pancreatic cases was calculated using age- and
sex- and birthplace-(Utah or not Utah) specific rates of pancreatic
cancer estimated within the UPDB, applied to all of the descendants
in each family. Of the 60 families, 45 had sufficient genealogic
information available (at least three generations of individuals in the
UPDB) to facilitate these calculations.
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